From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
LMP517 (NSC 781517) a indenoisoquinoline, is a potent a dual TOP1 and TOP2 inhibitor. LMP517 shows better antitumor activity than its parent compound LMP744 (HY-U00248) against H82 (Small Cell Lung Cancer) xenografts. LMP517 induces TOP1 cleavage complexes (TOP1ccs) and TOP2ccs .
Indotecan (LMP-400), an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC50s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis .
LMP7/LMP2-IN-1 (Compound 19) is the orally active inhibitor for immunoproteasome subunits LMP7 and LMP2 with IC50 of 257 and 10 nM. LMP7/LMP2-IN-1 reduces the generation of antibody, downregulates the cells in spleen germinal center B and in plasma in NP-OVA-immunized mice, and can be used in research about autoimmune diseases .
LMP7-IN-1, a Boronic acid derivative, is a potent and selective immunoproteasome subunit LMP7 (β5i) inhibitor with an IC50 of 1.83 nM (WO2021143923A1; compound 20) .
Indotecan hydrochloride, an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC50s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan hydrochloride prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis .
Arylquin 1, a prostate-apoptosis-response-4 (Par-4) secretagogue, targets vimentin to induce Par-4 secretion. Arylquin 1 induces non-apoptotic cell death in cancer cells through the induction of lysosomal membrane permeabilization (LMP) .
KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC50s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease .
ML604440 is a specific and cell-permeable Proteasome β1i(LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor .
Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .
M3258 is an orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. M3258 shows strong antitumor efficacy in multiple myeloma xenograft models. M3258 leads to a significant and prolonged suppression of tumor LMP7 activity and ubiquitinated protein turnover and the induction of apoptosis in multiple myeloma cells .
PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities .
Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases .
Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases .
(R)-PR-924 is the isomer of PR-924 (HY-123587), and can be used as an experimental control. PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities .
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .
Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells .
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 +CD8 + central and CD3 +CD8 + effector memory T cells and decrease the percentage of CD3 + T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity .
UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey . UK-101 induces cell apoptosis and can be used for the study of prostate cancer .
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (Ki=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .
NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B. This process triggers lysosomal swelling, membrane permeabilization (LMP), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway. NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells (IC50 ~10 μM) while showing low toxicity to normal cells (IC50 > 60 μM) .
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .
NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B. This process triggers lysosomal swelling, membrane permeabilization (LMP), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway. NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells (IC50 ~10 μM) while showing low toxicity to normal cells (IC50 > 60 μM) .
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity .
HLA-A*0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A*0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A*0201 LMP2 Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A*0201 LMP2 Complex protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Protein, Human (HEK293, His-Avi), has molecular weight of 52-56 kDa.
HLA-A*0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A*0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A*0201 LMP2 Complex Protein, Human (Biotinylated, HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A*0201 LMP2 Complex protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Protein, Human (Biotinylated, HEK293, His-Avi), has molecular weight of 51-60 kDa.
HLA-A*0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A*0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A*0201 LMP2 Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A*0201 LMP2 Complex Tetramer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.
HLA-A*0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A*0201 WT-1 Complex Tetramer is recognized within the MHC class I family. Chimeric HLA-A*0201 LMP2 Protein, Human&Mouse (HEK293, His-Avi) is the recombinant mouse-derived Chimeric HLA-A*0201 LMP2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. Chimeric HLA-A*0201 LMP2 Protein, Human&Mouse (HEK293, His-Avi), has molecular weight of 52-65 kDa.
HLA-A*1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 51-60 kDa.
HLA-A*0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A*0201 WT-1 Complex Tetramer is recognized within the MHC class I family. Chimeric HLA-A*0201 LMP2 Tetramer Protein, Human&Mouse (HEK293, His-Avi) is the recombinant mouse-derived Chimeric HLA-A*0201 LMP2 Tetramer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. Chimeric HLA-A*0201 LMP2 Tetramer Protein, Human&Mouse (HEK293, His-Avi), has molecular weight of 260-265 kDa.
HLA-A*1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A*1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A*1101 LMP2 Complex Protein, Human (Biotinylated, SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Protein, Human (Biotinylated, SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 51-60 kDa.
HLA-A*1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A*1101 LMP2 Complex Tetramer Protein, Human (SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Tetramer Protein, Human (SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 260-265 kDa.
PSMB6 protein is a component of the 20S core proteasome complex and participates in ubiquitin-dependent protein degradation within the 26S proteasome.This complex maintains protein homeostasis by eliminating misfolded or unnecessary proteins.PSMB6 Protein, Mouse (His) is the recombinant mouse-derived PSMB6 protein, expressed by E.coli , with N-His labeled tag.
Proteasome 20S LMP7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 30 kDa, targeting to Proteasome 20S LMP7. It can be used for WB,ICC,IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
Proteasome beta 8 Antibody (YA684) is a non-conjugated and Mouse origined monoclonal antibody about 30 kDa, targeting to Proteasome beta 8 (3G3). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Rat.
PDLIM7 Antibody (YA1566) is a biotin-conjugated non-conjugated IgG antibody, targeting PDLIM7, with a predicted molecular weight of 50 kDa (observed band size: 50 kDa). PDLIM7 Antibody (YA1566) can be used for WB experiment in human background.
PSMB10 Antibody (YA1767) is a biotin-conjugated non-conjugated IgG antibody, targeting PSMB10, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). PSMB10 Antibody (YA1767) can be used for WB experiment in human, rat background.
Proteasome beta 9 Antibody (YA1747) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1747), targeting Proteasome beta 9, with a predicted molecular weight of 23 kDa (observed band size: 23 kDa). Proteasome beta 9 Antibody (YA1747) can be used for WB, ICC/IF experiment in human, mouse, rat background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
